In cancer, well over 90% of mutations found in patient tumors are deemed ‘non-actionable’. Many proteins with ‘non-actionable’ mutations are investigated by scientists who study RNA biology, in ...

Bodybuilders and cellular mechanisms agree generating protein is a heavy lift. To complete the task, cells rely on complexes called spliceosomes. These molecular machines snip extra bits out of our ...

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. As late-stage PCT clinical ...